
ABSTRACT A characteristic hallmark of chronic kidney disease (CKD) is progressive renal fibrosis, for which effective therapeutic strategies remain limited. This study investigated the renoprotective effects of Lactococcus lactis subsp. hordniae LB‐P22 in an adenine‐induced murine model of renal fibrosis, focusing on protein disulfide isomerase A1 (PDIA1)‐mediated redox regulation of dynamin‐related protein 1 (Drp1) as a central mechanism controlling mitochondrial dynamics and fibrotic progression. Mice fed a 0.75% adenine diet for three weeks developed tubular injury, interstitial fibrosis, and impaired renal function. LB‐P22 (10 8 or 10 9 CFU) was administered orally once daily from one week before adenine feeding until sacrifice on day 28, and attenuated these changes, with statistically significant improvement observed mainly at 10 9 CFU. LB‐P22 reduced fibrotic remodelling and pro‐inflammatory cytokine expression (TNF‐α, IL‐6, and IL‐1β), increased superoxide dismutase, catalase, and glutathione peroxidase activities, and lowered malondialdehyde. LB‐P22 also attenuated TGF‐β1/MAPK signalling and shifted the balance of mitochondrial dynamics away from fission: adenine upregulated Dnm1l and Mff and downregulated Opa1 and Mfn2 , and LB‐P22 partially reversed these changes. Renal PDIA1 protein and activity were reduced by adenine and increased by high‐dose LB‐P22, whereas Drp1 sulfenylation showed the opposite pattern, consistent with the reported role of PDIA1 as a thiol reductase for Drp1. These changes were accompanied by lower mitochondrial ROS. Collectively, these findings indicate that LB‐P22 attenuates adenine‐induced renal fibrosis in association with reduced inflammation, improved redox balance, and partial normalization of mitochondrial dynamics, supporting its potential as a probiotic‐based candidate for CKD.
ABSTRACT Stress granules (SGs) are dynamic, membrane‐less ribonucleoprotein condensates that assemble via liquid–liquid phase separation in the cytoplasm when translation initiation is impaired. SG formation commonly accompanies translational repression and may subsequently redistribute selected RNAs and signalling proteins, thereby linking cellular stress to innate immunity. Many viruses have been reported to inhibit SG assembly or recruit SG‐associated proteins, whereas bacterial and mycobacterial infections can activate eIF2α phosphorylation and are associated with SG‐like responses. Respiratory pathogens exhibit diverse SG phenotypes: coronaviruses and influenza viruses generally limit canonical SG assembly, although individual SARS‐CoV‐2 proteins have been reported to exert opposing effects; respiratory syncytial virus replication correlates with G3BP1 and SG‐positive cells, but an SG‐specific mechanism remains unresolved; and Mycobacterium tuberculosis induces persistent G3BP1‐positive granules together with translational and metabolic suppression. Studies in bacterial model systems also suggest that pathogen‐intrinsic protein condensates may influence dormancy and antibiotic tolerance, but whether analogous condensates form during respiratory infection remains unknown. Understanding how respiratory pathogens alter the ISR, translation and SG‐associated pathways may reveal pathogen‐ and context‐specific therapeutic opportunities. This review summarizes mechanistic advances in coronavirus‐G3BP interactions, SG biology and pathogen‐specific observations; critically distinguishes causal evidence from correlation, as well as SG‐dependent from SG‐independent functions of commonly manipulated proteins; and discusses antibiotic tolerance and therapeutic hypotheses in light of their current evidentiary limitations.
ABSTRACT Bronchopulmonary dysplasia (BPD) is a heterogeneous developmental lung disorder resulting from the interaction between antenatal susceptibility and postnatal injury. Increasing evidence suggests that its biological origins may precede preterm birth, with placental dysfunction, fetal growth restriction, inflammation and oxidative stress influencing pulmonary developmental trajectories before exposure to the extrauterine environment. MicroRNAs (miRNAs), small non‐coding RNAs that regulate gene expression at the post‐transcriptional level, are emerging as potential molecular mediators linking these fetal and neonatal processes. This educational review examines miRNA dysregulation across the fetal–neonatal continuum of BPD. We first discuss the role of miRNAs in physiological lung development and their disruption following premature birth. We then explore how placental dysfunction and fetal growth restriction may influence miRNA networks, including placenta‐enriched C19MC miRNAs, thereby contributing to antenatal susceptibility to BPD. Particular attention is given to miRNA‐mediated regulation of pulmonary angiogenesis and VEGF signaling and to the bidirectional relationship between miRNAs and oxidative stress, including modulation of NRF2‐dependent antioxidant responses. Beyond their mechanistic relevance, miRNAs offer potential translational opportunities. Their stability and detectability across different biological compartments—including placenta, cord blood, peripheral blood, respiratory samples and extracellular vesicles—make them attractive candidates for longitudinal biomarker profiling, while experimental modulation using miRNA mimics and inhibitors provides proof of concept for future therapeutic approaches. However, heterogeneity in biological sampling, analytical methods, developmental timing and BPD phenotypes, together with challenges in tissue‐specific delivery and off‐target effects, currently limit clinical translation. Rather than identifying a single ‘BPD miRNA’, future research should focus on dynamic, multi‐compartment miRNA networks integrating antenatal programming with postnatal exposures. Such an approach may improve molecular endotyping, early risk stratification and ultimately the development of individualized preventive and therapeutic strategies for BPD.
Autophagy plays complex, context-dependent roles in lung adenocarcinoma (LUAD), but the upstream molecular drivers that govern this process remain elusive. NLRC4 is classically defined as a pyroptosis-inducing inflammasome sensor, yet its non-canonical, tumour-intrinsic function in LUAD progression remains largely unexplored. Through multi-omics screening and prognostic modelling across TCGA and GEO datasets, we identified NLRC4 as a critical autophagy-associated protective factor, which was validated in an institutional cohort of paired LUAD tissues. In vitro and in vivo assays, autophagic flux monitoring, reciprocal co-immunoprecipitation and genetic rescue experiments were employed to elucidate the underlying mechanism. NLRC4 protein was markedly downregulated in LUAD tissues alongside the tumour suppressor PTEN, correlating with advanced TNM stage and poor overall survival. Functionally, restoring NLRC4 expression inhibited LUAD cell proliferation, motility, invasion and epithelial-mesenchymal transition in vitro, whereas NLRC4 depletion accelerated xenograft tumour growth in vivo. Crucially, NLRC4 selectively stimulated complete autophagic flux without triggering Caspase-1/Gasdermin cleavage or lytic pyroptotic death. Mechanistically, NLRC4 physically interacted with NFKB1 (p105/p50) in a tumour-selective manner, relieving NF-kappa B-mediated transcriptional repression of PTEN. This restored PTEN expression, thereby tonically dampening the PI3K/AKT/mTOR signalling cascade. Genetic blockade of autophagy (siATG5) or PTEN ablation largely reversed the tumour-suppressive effects of NLRC4, confirming the functional dependency on the PTEN-autophagy axis. Our study establishes a non-canonical, tumour-intrinsic role for NLRC4 in restraining LUAD progression via the PI3K/AKT/mTOR axis to induce protective autophagy, positioning it as a promising prognostic biomarker and potential therapeutic target.
After undergoing ADT treatment, drug resistance has emerged as a major hindrance in the treatment of prostate cancer, with enzalutamide resistance being the most notable. Our objective was to identify a new drug-resistance mechanism present in post-ADT-treatment patients. Utilizing proteomic sequencing, we discovered abnormal increases in IGF1R levels. Subsequent sequencing and bioinformatic analyses showed that IGF1R could cause abnormal changes in the tricarboxylic acid cycle (TCA cycle) and oxidative phosphorylation. This phenomenon may be due to IGF1R's influence on the distribution of mitochondrial Ca2+ and the production of reactive oxygen species (ROS). Our CHIP and dual-luciferase experiments confirmed the regulatory relationship between IGF1R and MICU1. The fluorescent results of Ca2+ and ROS also confirmed that IGF1R could regulate mitochondrial Ca2+ distribution and ROS production. Our team validated the relationship between IGF1R and drug resistance through cell phenotype experiments, and explored its potential as a therapeutic target through a fa-ci curve. Finally, we verified the effectiveness of the mechanisms we found through a xenograft assay. Our study confirms the potential for IGF1R as a clinical therapeutic target.